Literature DB >> 28098937

Sodium selenate treatment improves symptoms and seizure susceptibility in a malin-deficient mouse model of Lafora disease.

Gentzane Sánchez-Elexpuru1,2, José M Serratosa1,2, Marina P Sánchez1,2.   

Abstract

OBJECTIVE: To search for new therapies aimed at ameliorating the neurologic symptoms and epilepsy developing in patients with Lafora disease.
METHODS: Lafora disease is caused by loss-of-function mutations in either the EPM2A or EPM2B genes. Epm2a-/- and Epm2b-/- mice display neurologic and behavioral abnormalities similar to those found in patients. Selenium is a potent antioxidant and its deficiency has been related to the development of certain diseases, including epilepsy. In this study, we investigated whether sodium selenate treatment improved the neurologic alterations and the hyperexcitability present in the Epm2b-/- mouse model.
RESULTS: Sodium selenate ameliorates some of the motor and memory deficits and the sensitivity observed with pentylenetetrazol (PTZ) treatments in Epm2b-/- mice. Neuronal degeneration and gliosis were also diminished after sodium selenate treatment. SIGNIFICANCE: Sodium selenate could be beneficial for ameliorating some symptoms that present in patients with Lafora disease. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Epm2b−/− mouse; Lafora bodies; Oxidative stress; Sodium selenate

Mesh:

Substances:

Year:  2017        PMID: 28098937      PMCID: PMC5495962          DOI: 10.1111/epi.13656

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  39 in total

1.  Progressive familial myoclonic epilepsy in three families: its clinical features and pathological basis.

Authors:  D G HARRIMAN; J H MILLAR; A C STEVENSON
Journal:  Brain       Date:  1955-09       Impact factor: 13.501

2.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

4.  A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).

Authors:  J M Serratosa; P Gómez-Garre; M E Gallardo; B Anta; D B de Bernabé; D Lindhout; P B Augustijn; C A Tassinari; R M Malafosse; M Topcu; D Grid; C Dravet; S F Berkovic; S R de Córdoba
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

5.  Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models.

Authors:  Nigel C Jones; Thanh Nguyen; Niall M Corcoran; Dennis Velakoulis; Tracy Chen; Robert Grundy; Terence J O'Brien; Christopher M Hovens
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

6.  Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.

Authors:  Rajat Puri; Toshimitsu Suzuki; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

7.  Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.

Authors:  Shi-Jie Liu; Ping Zheng; David K Wright; Gabi Dezsi; Emma Braine; Thanh Nguyen; Niall M Corcoran; Leigh A Johnston; Christopher M Hovens; Jamie N Mayo; Matthew Hudson; Sandy R Shultz; Nigel C Jones; Terence J O'Brien
Journal:  Brain       Date:  2016-06-11       Impact factor: 13.501

Review 8.  Selenium intake, mood and other aspects of psychological functioning.

Authors:  David Benton
Journal:  Nutr Neurosci       Date:  2002-12       Impact factor: 4.994

9.  Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.

Authors:  Jordi Valles-Ortega; Jordi Duran; Mar Garcia-Rocha; Carles Bosch; Isabel Saez; Lluís Pujadas; Anna Serafin; Xavier Cañas; Eduardo Soriano; José M Delgado-García; Agnès Gruart; Joan J Guinovart
Journal:  EMBO Mol Med       Date:  2011-08-29       Impact factor: 12.137

10.  Phosphoproteomic profiling of selenate-treated Alzheimer's disease model cells.

Authors:  Ping Chen; Lixiang Wang; Yong Wang; Shuiming Li; Liming Shen; Qiong Liu; Jiazuan Ni
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more
  13 in total

1.  Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion.

Authors:  M Kathryn Brewer; Annette Uittenbogaard; Grant L Austin; Dyann M Segvich; Anna DePaoli-Roach; Peter J Roach; John J McCarthy; Zoe R Simmons; Jason A Brandon; Zhengqiu Zhou; Jill Zeller; Lyndsay E A Young; Ramon C Sun; James R Pauly; Nadine M Aziz; Bradley L Hodges; Tracy R McKnight; Dustin D Armstrong; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-07-25       Impact factor: 27.287

Review 2.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

Review 3.  Lafora disease: from genotype to phenotype.

Authors:  Rashmi Parihar; Anupama Rai; Subramaniam Ganesh
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 4.  Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions.

Authors:  Victoria M Golub; Doodipala Samba Reddy
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

5.  Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia-Reperfusion Injury.

Authors:  Qing-Zhang Tuo; Shashank Masaldan; Adam Southon; Celeste Mawal; Scott Ayton; Ashley I Bush; Peng Lei; Abdel Ali Belaidi
Journal:  Neurotherapeutics       Date:  2021-09-08       Impact factor: 6.088

6.  Trehalose Treatment in Zebrafish Model of Lafora Disease.

Authors:  Stefania Della Vecchia; Asahi Ogi; Rosario Licitra; Francesca Abramo; Gabriele Nardi; Serena Mero; Silvia Landi; Roberta Battini; Federico Sicca; Gian Michele Ratto; Filippo Maria Santorelli; Maria Marchese
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

Review 7.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

8.  Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2020-10-22       Impact factor: 5.590

Review 9.  Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.

Authors:  Pascual Sanz; José Maria Serratosa; Marina P Sánchez
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

10.  Ppp1r3d deficiency preferentially inhibits neuronal and cardiac Lafora body formation in a mouse model of the fatal epilepsy Lafora disease.

Authors:  Lori Israelian; Silvia Nitschke; Peixiang Wang; Xiaochu Zhao; Ami M Perri; Jennifer P Y Lee; Brandy Verhalen; Felix Nitschke; Berge A Minassian
Journal:  J Neurochem       Date:  2020-10-10       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.